Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 Antibody in Thai Community Hospitals

View ORCID ProfileTanawin Nopsopon, View ORCID ProfileKrit Pongpirul, Korn Chotirosniramit, View ORCID ProfileNarin Hiransuthikul
doi: https://doi.org/10.1101/2020.06.24.20139188
Tanawin Nopsopon
1Lecturer, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tanawin Nopsopon
Krit Pongpirul
2Assistant Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4Bumrungrad International Hospital, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krit Pongpirul
  • For correspondence: doctorkrit@gmail.com
Korn Chotirosniramit
5Medical Student, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narin Hiransuthikul
6Professor, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Narin Hiransuthikul
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background COVID-19 seroprevalence data has been scarce, especially in less developed countries with a relatively low infection rate.

Methods A locally developed rapid IgM/IgG test kit was used for screening hospital staff and patients who required procedural treatment or surgery in 52 hospitals in Thailand from April 8 to June 26, 2020. A total of 857 participants were tested—675 were hospital staff and 182 were pre-procedural patients. (Thai Clinical Trials Registry: TCTR20200426002)

Results Overall, 5.5% of the participants (47 of 857) had positive immunoglobulin M (IgM), 0.2% (2 of 857) had positive immunoglobulin G (IgG) and IgM. Hospitals located in the Central part of Thailand had the highest IgM seroprevalence (11.9%). Preprocedural patients had a higher rate of positive IgM than the hospital staff (12.1% vs. 3.7%). Participants with present upper respiratory tract symptoms had a higher rate of positive IgM than those without (9.6% vs. 4.5%). Three quarters (80.5%, 690 of 857) of the participants were asymptomatic, of which, 31 had positive IgM (4.5%) which consisted of 20 of 566 healthcare workers (3.5%) and 11 of 124 preprocedural patients (8.9%).

Conclusions COVID-19 antibody test could detect a substantial number of potential silent spreaders in Thai community hospitals. Antibody testing should be encouraged for mass screening, especially in asymptomatic individuals.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Thai Clinical Trials Registry: TCTR20200426002

Funding Statement

No external funding is received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Board of Chulalongkorn University (IRB No.236/63) and 18 general hospitals. Given no ethics committees were available in the participating community hospitals, participation in this study was approved by the hospital directors or representatives. All participants provided written informed consent. (Thai Clinical Trials Registry: TCTR20200426002)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available from the corresponding author upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 Antibody in Thai Community Hospitals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 Antibody in Thai Community Hospitals
Tanawin Nopsopon, Krit Pongpirul, Korn Chotirosniramit, Narin Hiransuthikul
medRxiv 2020.06.24.20139188; doi: https://doi.org/10.1101/2020.06.24.20139188
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 Antibody in Thai Community Hospitals
Tanawin Nopsopon, Krit Pongpirul, Korn Chotirosniramit, Narin Hiransuthikul
medRxiv 2020.06.24.20139188; doi: https://doi.org/10.1101/2020.06.24.20139188

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (157)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (852)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8527)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1731)
  • Geriatric Medicine (166)
  • Health Economics (370)
  • Health Informatics (1232)
  • Health Policy (615)
  • Health Systems and Quality Improvement (465)
  • Hematology (196)
  • HIV/AIDS (367)
  • Infectious Diseases (except HIV/AIDS) (10258)
  • Intensive Care and Critical Care Medicine (550)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (209)
  • Neurology (1662)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (321)
  • Occupational and Environmental Health (450)
  • Oncology (918)
  • Ophthalmology (261)
  • Orthopedics (99)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (532)
  • Pharmacology and Therapeutics (245)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1751)
  • Public and Global Health (3814)
  • Radiology and Imaging (620)
  • Rehabilitation Medicine and Physical Therapy (316)
  • Respiratory Medicine (518)
  • Rheumatology (204)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (188)
  • Toxicology (36)
  • Transplantation (99)
  • Urology (74)